Skip to main content

Table 4 Antithrombotic therapy in patients with and without care coordination during the campaign period

From: Impact of care coordination on oral anticoagulant therapy among patients with atrial fibrillation in routine clinical practice in Japan: a prospective, observational study

  With care coordination
N = 13
Without care coordination
N = 77
Antithrombotic therapy 11 (84.6) 59 (76.6)
 Oral anticoagulant agents 9 (69.2) 53 (68.8)
  Warfarin 1 (11.1) 10 (18.9)
  DOACs 8 (88.9) 43 (81.1)
 Antiplatelet agents 2 (15.4) 8 (10.4)
CHADS2 score low (score: 0) N = 0 N = 6
 Oral anticoagulant agents 0 (0.0) 2 (33.3)
  Warfarin 0 (0.0) 0 (0.0)
  DOACs 0 (0.0) 2 (100.0)
CHADS2 score intermediate (score: 1) N = 3 N = 7
 Oral anticoagulant agents 2 (66.7) 7 (100.0)
  Warfarin 0 (0.0) 3 (42.9)
  DOACs 2 (100.0) 4 (57.1)
CHADS2 score high (score: ≥2) N = 10 N = 64
 Oral anticoagulant agents 7 (70.0) 44 (68.8)
  Warfarin 1 (14.3) 7 (15.9)
  DOACs 6 (85.7) 37 (84.1)
OAC therapy based on JCS 2013 guidelines 9 (69.2) 55 (71.4)
  1. Data are n (%)
  2. Abbreviations: JCS 2013 Japanese guidelines for pharmacotherapy of atrial fibrillation, DOACs Direct oral anticoagulants